IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Marc Humbert, Jean Bousquet, Claus Bachert, Oscar Palomares, Pascal Pfister, Ioannis Kottakis, Xavier Jaumont, Simon Francis Thomsen, Nikolaos G. Papadopoulos

Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechanism. Multimorbidities of allergic asthma may influence asthma control, its severity, and patients' response to treatment, and contribute to the overall socioeconomic burden of the disease. Immunoglobulin E (IgE) is known to play a central role in the pathogenesis of various allergic diseases, including asthma. Thus, IgE-mediated immunologic pathways present an attractive target for intervention in asthma and multimorbidities. In this review, we discuss the most frequently reported IgE-mediated multimorbidities in allergic asthma, including allergic rhinitis, rhinoconjunctivitis, atopic dermatitis, vernal keratoconjunctivitis, chronic rhinosinusitis with nasal polyps, food allergies, and allergic bronchopulmonary aspergillosis. Omalizumab is a recombinant humanized monoclonal antibody against IgE and has been in use to treat allergic asthma for more than a decade. We comprehensively review the clinical evidence for omalizumab in the treatment of the aforementioned multimorbidities in allergic asthma. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
OriginalsprogEngelsk
TidsskriftThe Journal of Allergy and Clinical Immunology: In Practice
Vol/bind7
Udgave nummer5
Sider (fra-til)1418-1429
ISSN2213-2198
DOI
StatusUdgivet - 2019

ID: 228531060